The Effectiveness of the Drug Cortinin in the Treatment of Patients with Cirrhosis of the Liver

Liver cirrhosis remains one of the most serious chronic diseases worldwide, characterized by progressive fibrosis, hepatocellular necrosis, and the loss of functional hepatic tissue. Despite significant advances in hepatology, therapeutic options that can slow or reverse liver fibrosis remain limited. In recent years, Cortinin, a pharmacological agent with hepatoprotective, anti-inflammatory, and metabolic-regulating properties, has attracted increasing attention as a promising treatment option for patients with cirrhosis of the liver.

This article review summarizes current research findings on the mechanisms, clinical efficacy, and safety of Cortinin in cirrhotic patients. By examining experimental and clinical data published over the last two decades, the paper evaluates the potential of Cortinin as an adjunct therapy for chronic liver disease. Evidence suggests that Cortinin improves hepatic metabolism, reduces fibrosis progression, enhances antioxidant defense, and promotes regeneration of hepatocytes.